April 02, 2022
Cover Story
35
4
The need to increase efficiency and productivity is driving adoption.
April 02, 2022
Development
35
4
The recent success of mRNA vaccines has opened the door for further and future development of nucleic acid-based therapies.
April 02, 2022
Upstream Processing
35
4
The growing demand for antibody and other bio-therapeutics will require long-term scale-up solutions.
April 01, 2022
Downstream Processing
35
4
The past year of downstream processing has brought innovations in pH sensitive antibody purification, single-use fermentation separators, and more.
April 01, 2022
Quality/Regulations
35
4
Data may be used to improve (or remove) a corrective action/preventive action.
April 01, 2022
Supply Chain
35
4
Taking key considerations into account along the cell therapy supply chain can set cell therapy developers up for success.
April 01, 2022
Manufacturing
35
4
As process controls adjust to a continuously shifting manufacturing landscape, implementation of information gathered from novel data analysis techniques has become a priority.
April 01, 2022
Outsourcing
35
4
The booming cell therapy market has created a need for capacity that outsourcing partners are ready to fill.
April 01, 2022
Analytics
35
4
Effective cleaning and disinfection along with contamination controls are imperative when operating and utilizing a cleanroom.
April 01, 2022
Outsourcing
35
4
BioPharm International spoke with Colleen Floreck, vice president, Global Marketing and Strategy, Catalent Cell and Gene Therapy about the specific requirements and challenges for expanding production of viral vectors.
April 01, 2022
Quality/Regulations
35
4
Performing corrective action and preventive action (CAPA) activities is often necessary to investigate a manufacturing deviation and prevent it from reoccurring. BioPharm International asked Joe O’Gorman, head of Global Operations at LZ Lifescience, a Cognizant Company, about the role technology plays in performing CAPAs.
April 01, 2022
Regulatory Beat
35
4
Quality metrics and more domestic production aim to avoid supply disruptions and drug shortages.
April 01, 2022
From the Editor
35
4
3D cell cultures could provide key avenues to unlocking critical information.
April 01, 2022
Ask The Expert
35
4
Experts Susan J. Schniepp, distinguished fellow for Regulatory Compliance Associates, and Steven J. Lynn, executive vice-president, Pharmaceuticals for Regulatory Compliance Associates, discuss the verification of compendial methods.
April 01, 2022
From the CEO
35
4
Advances in pharmaceutical neuroscience present an opportunity for pharmaceutical companies to stay ahead of the curve.